Accord Farma S.a. DE C.v.

Accord Farma S.A. de C.V. is a Mexican pharmaceutical company specializing in the importation and distribution of generic pharmaceutical products. Established in 2006, the company is headquartered in Mexico City, with its office located at Jaime Balmes #11, Torre D, Piso 3, Col. Los Morales Polanco, C.P. 11510, Miguel Hidalgo. (accordfarma.com.mx) Accord Farma operates as the Mexican representative of Intas Pharmaceuticals Ltd., a prominent Indian pharmaceutical manufacturer. (accordfarma.com.mx) The company plays a significant role in Mexico's pharmaceutical distribution network, focusing on the importation of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections.

Accord Farma's distribution network is centered in Mexico City, where it manages its operations and logistics. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic partnership with Intas Pharmaceuticals Ltd. suggests a robust supply chain infrastructure. This partnership likely facilitates efficient distribution within Mexico and potentially to other regions, leveraging Intas's global manufacturing and distribution capabilities.

In Mexico's pharmaceutical supply chain, Accord Farma S.A. de C.V. functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from Intas Pharmaceuticals Ltd., the company ensures a steady supply of generic medications to the Mexican market. This role is crucial in providing affordable healthcare options to the population, especially in the generic drug segment.

Accord Farma's sourcing strategy exhibits a high degree of concentration, with 99.5% of its imports from India supplied by Intas Pharmaceuticals Ltd. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. However, the consistent volume of shipments—171 out of 173 total shipments from India—indicates a stable and reliable relationship between Accord Farma and Intas Pharmaceuticals Ltd. The remaining 0.5% of imports from RPG Life Sciences Limited suggests minimal diversification in sourcing.

Accord Farma's supply chain resilience is closely tied to its exclusive partnership with Intas Pharmaceuticals Ltd. The lack of backup suppliers for the majority of its imports indicates a potential vulnerability to supply chain disruptions. Additionally, the limited diversity in imported formulations, with only five products across three therapeutic categories, suggests a narrow product range. This concentration may impact the company's ability to adapt to market changes or shifts in demand. Furthermore, the reliance on a single supplier raises concerns about exposure to shipping route disruptions and the need for stringent regulatory compliance from Intas Pharmaceuticals Ltd.

Accord Farma's concentrated sourcing strategy positions it as a key distributor of Intas Pharmaceuticals Ltd.'s products in Mexico, potentially offering competitive advantages through exclusive access to specific generic medications. However, this dependency also exposes the company to risks associated with supply chain disruptions and regulatory changes affecting its sole supplier. For Indian exporters seeking to become alternative suppliers, the limited diversification in Accord Farma's sourcing presents an opportunity to introduce additional products and mitigate the company's supply chain risks.

In Mexico, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) is the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharmaceutical imports includes the General Health Law and the Health Supplies Regulation. These regulations establish the framework for the importation, registration, and marketing of pharmaceutical products in Mexico. The marketing authorization pathway for Indian generics involves obtaining COFEPRIS approval, which requires compliance with specific documentation, quality standards, and clinical data to ensure the safety and efficacy of the imported products.

Import licensing requirements for pharmaceutical products in Mexico mandate that importers obtain a sanitary license from COFEPRIS. This license ensures that imported products meet the necessary health and safety standards. Good Manufacturing Practice (GMP) certificates recognized by COFEPRIS, such as those from the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S), are essential for the importation of pharmaceutical products. Accord Farma, as a distributor, must ensure that its suppliers hold valid GMP certifications to comply with Mexican regulations. Additionally, Accord Farma must possess wholesale distribution authorization from COFEPRIS to legally distribute pharmaceutical products within Mexico.

Imported pharmaceutical products must undergo batch testing to verify their quality, potency, and purity. Stability studies are required to ensure that products maintain their efficacy and safety throughout their shelf life. Labeling requirements stipulate that product information be provided in Spanish, including dosage instructions, indications, and storage conditions. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market. Accord Farma must ensure that its imported products comply with these quality and labeling standards to meet regulatory expectations and consumer safety.

Between 2024 and 2026, Mexico implemented several regulatory changes affecting pharmaceutical imports. These included stricter requirements for GMP certifications, enhanced pharmacovigilance reporting, and updated labeling standards to improve patient safety and product traceability. Accord Farma, as an importer, needed to adapt to these changes by ensuring that its suppliers met the new standards and that its imported products complied with the updated regulations.

Accord Farma's product strategy focuses on importing generic medications in the cardiovascular and oncology therapeutic areas. The significant import value of Telmisartan, a cardiovascular drug, indicates a strong market demand for affordable hypertension treatments. The inclusion of oncology drugs like Carboplatin, Etoposide, Docetaxel, and Mitoxantrone reflects the company's commitment to providing essential cancer therapies. This strategic focus aligns with the growing healthcare needs in Mexico, where chronic diseases and cancer are prevalent.

Accord Farma's sourcing strategy is centered on importing generic drugs from India, particularly from Intas Pharmaceuticals Ltd. The company's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a focus on ready-to-market products. India's established pharmaceutical manufacturing capabilities and cost-effectiveness make it a suitable source for Accord Farma's procurement needs. This sourcing approach allows Accord Farma to offer a range of generic medications to the Mexican market efficiently.

Based on its product mix, Accord Farma S.A. de C.V. serves the wholesale distribution segment of the Mexican pharmaceutical market. By importing and distributing generic medications, the company provides affordable healthcare options to various stakeholders, including retail pharmacies, hospitals, and government health programs. Its focus on high-demand therapeutic areas positions it as a key player in meeting the healthcare needs of the Mexican population.

There is a realistic opportunity for new Indian suppliers to enter Accord Farma's supply chain. The company's limited diversification in sourcing and its reliance on a single supplier for the majority of its imports suggest potential gaps that new suppliers could fill. Introducing additional products or alternative sources for existing products could help mitigate supply chain risks and enhance Accord Farma's product offerings. For Indian exporters, this presents an opportunity to establish partnerships and expand their market presence in Mexico.

Indian exporters seeking to supply Accord Farma S.A. de C.V. must ensure that their products comply with Mexican regulatory standards. This includes obtaining GMP certifications recognized by COFEPRIS, such as EU GMP, WHO GMP, or PIC/S. Products must also meet labeling requirements, including Spanish language labeling and serialization mandates. Additionally, exporters should be prepared to provide necessary documentation for import licensing and quality assurance to facilitate the approval process with Accord Farma and Mexican authorities.

To establish a relationship with Accord Farma, Indian exporters should initiate contact by providing detailed product information, including GMP certifications, quality assurance documentation, and compliance with Mexican regulatory standards. Participating in tenders and responding to requests for proposals can also be effective strategies. Understanding the regulatory filing process and preparing for the necessary approvals from COFEPRIS will be crucial. Setting realistic timelines for product registration and market entry, considering the regulatory requirements and potential lead times, will help in planning a successful partnership.